ProQR Therapeutics - PRQR Stock Forecast, Price & News

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

ProQR Therapeutics Stock Performance

Shares of PRQR Stock remained flat at $0.84 during mid-day trading on Friday. 449,495 shares of the stock were exchanged, compared to its average volume of 328,121. ProQR Therapeutics has a 52 week low of $0.53 and a 52 week high of $9.09. The company has a debt-to-equity ratio of 0.38, a quick ratio of 7.27 and a current ratio of 7.27. The firm's fifty day moving average is $0.79 and its 200-day moving average is $1.36.

ProQR Therapeutics (NASDAQ:PRQR - Get Rating) last announced its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.03. The business had revenue of $1.39 million during the quarter, compared to analysts' expectations of $1.19 million. ProQR Therapeutics had a negative net margin of 1,859.05% and a negative return on equity of 53.02%. On average, equities research analysts forecast that ProQR Therapeutics will post -0.86 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on PRQR shares. JMP Securities dropped their price objective on shares of ProQR Therapeutics from $8.00 to $5.00 and set a "market outperform" rating on the stock in a research note on Thursday, April 14th. HC Wainwright decreased their target price on shares of ProQR Therapeutics from $4.00 to $2.00 in a research report on Monday, May 9th. Cantor Fitzgerald reissued an "overweight" rating on shares of ProQR Therapeutics in a research report on Monday, May 9th. StockNews.com raised shares of ProQR Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, May 9th. Finally, Chardan Capital decreased their target price on shares of ProQR Therapeutics from $8.00 to $2.50 and set a "buy" rating for the company in a research report on Thursday, April 14th. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, ProQR Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $7.43.